Based on the different roles of Smad3 and Smad2 in TGFβ signaling [29], [30] and the fact that Smad3, but not Smad2, mediates the liver fibrosis response [17], we thereby propose that NPLC0393 might supply a promising interest in the treatment of liver fibrosis with high specificity, although the detailed mechanism of such specificity needs to be further investigated. This evidence concerns the gene SMAD3 and Hepatic fibrosis.